IMMUNEXT PHARMACEUTICALS

R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.

IMMUNEXT PHARMACEUTICALS is a biotech company in Lebanon, United States, founded in 2016. It has raised $11.4M across 6 rounds, most recently a $3.0M Grant in June 2021.

Employees
11–50
Founded
2016
Total Funding
$11.4M
Last Round
$3.0M GrantJun 2021
Rounds
6

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 6 funding rounds for this company. to use credits for reveals, or explore the API.

About

ImmuNext is a biotech developing immune-based therapeutics for autoimmune disease, cancer, and transplant rejection. Its lead program is a human monoclonal antibody targeting VISTA, an immune checkpoint protein, designed to suppress overactive immune responses in lupus and other autoimmune conditions. The company has formed partnerships with major pharmaceutical firms including Eli Lilly, Sanofi, and Janssen, and has received multiple SBIR/STTR awards from NIH to advance its antibody pipeline.

Funding History

Data from Indexed.vcUpdated
GrantSBIR Phase II (NIH)Jun 2021
$3.0M

5 more events

  • Grant2018
  • Grant2018
  • Grant2017

Funding: Grant. Amounts, valuations, and investors where available.

Companies in related industries

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

IMMUNEXT PHARMACEUTICALS on Indexed.vc
<a href="https://indexed.vc/companies/immunext-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/immunext-pharmaceuticals" alt="IMMUNEXT PHARMACEUTICALS on Indexed.vc" width="260" height="76" /></a>